Instituto Universitario de Investigación en Neuroquímica
Centre/Institute
Medical University of Vienna
Viena, AustriaPublications in collaboration with researchers from Medical University of Vienna (13)
2023
-
APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke
Frontiers in Neurology, Vol. 14
-
Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial
JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788
2022
-
Clinical trials in pediatric ALS: a TRICALS feasibility study
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 23, Núm. 7-8, pp. 481-488
-
First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers
Molecular Therapy - Nucleic Acids, Vol. 28, pp. 124-135
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2020
-
Assessing autophagy in archived tissue or how to capture autophagic flux from a tissue snapshot
Biology, Vol. 9, Núm. 3
2017
-
Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells
Oncotarget, Vol. 8, Núm. 7, pp. 11600-11613
2016
2015
-
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
Blood, Vol. 125, Núm. 1, pp. 90-101
-
Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells
International Journal of Cancer, Vol. 136, Núm. 9, pp. 2078-2090
2014
-
Programming of neural cells by (endo)cannabinoids: From physiological rules to emerging therapies
Nature Reviews Neuroscience, Vol. 15, Núm. 12, pp. 786-801
-
The expression of cannabinoid receptor 1 is significantly increased in atopic patients
Journal of Allergy and Clinical Immunology, Vol. 133, Núm. 3